Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $215M (up 16.6% year over year) with net income of $32M.
Q1 2026 key financials · XBRL
- Revenue
- $215M
- +16.6% YoY
- Net income
- $32M
- −28.7% YoY
- Operating margin
- 17.3%
- Gross margin
- 79.3%
- EPS (diluted)
- $0.55
- −29.5% YoY
Source: XBRL data from the Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 10-Q on SEC EDGAR. USD.
Harmony Biosciences Holdings, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- WAKIX average patients approximately 8,500 for quarter ended March 31, 2026
- Formulary access secured for more than 80% of insured U.S. lives
- Near-term outlook: Pitolisant GR NDA submission targeted second quarter 2026; R&D and commercial expenses expected to increase
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 rather than risk disclosures
- TLA Credit Agreement defaults incorporated by reference from Note 10: Debt
- April 2026 executive employment and separation agreements disclosed as new exhibits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Harmony Biosciences Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.